You are here

Report: First Class of Biosimilars to Enter U.S. Market Could Generate $1.8 Billion in Sales by 2023

Oncologists expected to embrace lower-cost alternatives to Neupogen

Decision Resources Group, a health care research firm located in Burlington, Mass., reports that sales of biosimilar versions of the granulocyte colony-stimulating factors (G-CSFs) filgrastim, which is currently pending FDA approval, and pegfilgrastim could reach $1.8 billion in the U.S. by 2023.

Medical oncologists and hematologist-oncologists surveyed in France and Germany indicated that they would prescribe future biosimilar G-CSFs, such as pegfilgrastim, to a significantly higher percentage of eligible patients compared with biosimilars of monoclonal antibodies (MAbs). In addition, a greater proportion of surveyed oncologists indicated that they expected to start prescribing biosimilar G-CSFs within 6 months of availability compared with biosimilar MAbs.

“Filgrastim biosimilars have performed well in Europe, with sales exceeding the reference product in many countries. Now those biosimilars are on the verge of entering the U.S. market, where we expect U.S. oncologists to swiftly adopt these tried-and-tested lower-cost alternatives to Amgen’s Neupogen [filgrastim],” said analyst Kate Keeping.

Most of the surveyed oncologists indicated that they have a preferred biosimilar filgrastim product, and that their preference is driven by which manufacturer they trust most.

The proportion of surveyed oncologists that indicated that regulatory approval would not allay all of their concerns about equivalence between a biosimilar and the reference brand was higher for MAbs than for G-CSFs.

“Surveyed oncologists’ responses indicated that they view the use of biosimilars differently in a therapeutic setting, compared with a supportive-care setting,” Keeping said.

Source: BioTrends Research Group; November 19, 2014.


Recent Headlines

Patients Had Improved Lung Function, Fewer Exacerbations
Particularly Serious: Antidepressants, Drugs for Parkinson’s and Epilepsy
Drug “Remarkably Effective” at Killing Range of Gram-Positive Bacteria
Up to 70% Greater Risk of Bacterial Infection, 48% Risk for Fungal Infection
Most Women Undergoing Surgery for Suspected Cancer Do Not Have It
Specific Monoclonal Antibodies Ensure Extreme Sensitivity, Accuracy
Record-High Number of Cases in France, Italy, Greece, Other Locations
Will Have a Longer Shelf Life Than Current, Expired Stockpile